PluriFRA:4DX 29 Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus rates FRA:4DX with a GF Score™ of 29/100 and a GF Value™ of €17.25. The stock has 6 warning signs investors should review. Among 741 Biotechnology companies, Pluri ranks worse than 134952.63% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Pluri's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4DX vs MRKR, VYNE, LGVN: Buyback Yield % Comparison
For the Biotechnology subindustry, Pluri's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pluri Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pluri's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Pluri's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pluri (FRA:4DX) has a Buyback Yield % of 0.00 as of Jul. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pluri and its competitors. According to the industry distribution chart, Pluri ranks #999999 out of 741 companies in the Biotechnology industry.
Is Pluri's Buyback Yield % too high?
Pluri's current Buyback Yield % is 0.00. Based on the distribution chart, Pluri ranks #999999 out of 741 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pluri has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Pluri's Buyback Yield % compare to MRKR and VYNE?
According to the Biotechnology industry distribution chart, Pluri ranks #999999 out of 741 companies for Buyback Yield %. This places Pluri in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Pluri and its competitors. Pluri's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pluri stock overvalued right now?
Pluri (FRA:4DX) has a current Buyback Yield % of 0.00. The stock's GF Value™ is €17.25, compared to a current price of €5.60 — trading 67.5% below its estimated fair value. The current Buyback Yield % is 0.00. Pluri's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Pluri (FRA:4DX), the current Buyback Yield % is 0.00 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pluri (FRA:4DX) Overvalued in 2026?
Based on GuruFocus' analysis, Pluri stock appears to be undervalued.
The current stock price of €5.60 is trading 67.5% below its estimated GF Value™ of €17.25.
Key valuation signals for FRA:4DX:
Buyback Yield %: 0.00
GF Value™: €17.25 vs. price of €5.60 (67.5% below fair value)
No single metric tells the full story. See the FRA:4DX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
29GF Score
Get the complete analysis for FRA:4DX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4DX has been successfully added to your 
